Taro Announces Resignation of Chief Financial Officer
December 06 2019 - 8:45AM
Business Wire
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the
“Company”) announced today that it has accepted the resignation of
its Chief Financial Officer, Mariano Balaguer, effective January 3,
2020. Mr. Balaguer is leaving to accept the position of CFO at
another company.
Mr. Uday Baldota, Taro’s CEO, stated, “On behalf of the Company,
we want to thank Mariano for his many contributions to the Company
during his three plus year tenure at Taro and his leadership of
Taro’s finance team. We wish him continued success in his new
position.”
The company has initiated a search for a successor as CFO.
About Taro
Taro Pharmaceutical Industries Ltd. is a multinational,
science-based pharmaceutical company, dedicated to meeting the
needs of its customers through the discovery, development,
manufacturing and marketing of the highest quality healthcare
products. For further information on Taro Pharmaceutical Industries
Ltd., please visit the Company’s website at www.taro.com.
SAFE HARBOR STATEMENT
Certain statements in this release are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements include, but are not limited
to, statements that do not describe historical facts or that refer
or relate to events or circumstances the Company “estimates,”
“believes,” or “expects” to happen or similar language, and
statements with respect to the Company’s financial performance,
availability of financial information, and estimates of financial
results and information for fiscal year 2020. Although the Company
believes the expectations reflected in such forward-looking
statements to be based on reasonable assumptions, it can give no
assurances that its expectations will be attained. Factors that
could cause actual results to differ include general domestic and
international economic conditions, industry and market conditions,
changes in the Company's financial position, litigation brought by
any party in any court in Israel, the United States, or any country
in which Taro operates, regulatory and legislative actions in the
countries in which Taro operates, and other risks detailed from
time to time in the Company’s SEC reports, including its Annual
Reports on Form 20-F. Forward-looking statements are applicable
only as of the date on which they are made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191206005053/en/
William J. Coote VP, Treasurer (914) 345-9001
William.Coote@taro.com
Taro Pharmaceutical Indu... (NYSE:TARO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Taro Pharmaceutical Indu... (NYSE:TARO)
Historical Stock Chart
From Sep 2023 to Sep 2024